Literature DB >> 16956945

Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.

Carmilia Jiménez-Ramírez1, Andrew J Brooks, Linus Plym Forshell, Konstantin Yakimchuk, Bo Zhao, Tacha Zi Fulgham, Clare E Sample.   

Abstract

Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA-3C) is essential for EBV-mediated immortalization of human B lymphocytes and regulates both the cell cycle and transcription. Transient reporter gene assays have implicated a pivotal role for EBNA-3C in the regulation of transcription of the majority of latency-associated genes expressed during the EBV growth program, including the viral oncoprotein LMP-1. To examine the regulation of latency gene expression by EBNA-3C, we generated an EBV-positive cell line that inducibly expresses EBNA-3C. This cell line allowed us to examine expression from the endogenous latency gene promoters in the context of an actual latent infection and the presence of other EBNA proteins, in particular EBNA-2, which is presumed to coregulate transcription with EBNA-3C. EBNA-3C induced the expression of both LMP-1 and LMP-2B mRNAs from the bidirectional LMP-1/LMP-2B promoter. In contrast, no effect was seen on expression from the common EBNA promoter Cp, which is responsive to EBNA-3C in reporter assays. Activation of LMP expression was not the consequence of increases in EBNA-2, PU.1 or Spi-B transcription factors, all of which are believed to be critical for activation of LMP-1. Chromatin immunoprecipitation assays furthermore indicated that EBNA-3C is present at the bidirectional LMP-1/LMP-2B promoter. These results indicate that EBNA-3C directly activates the expression of LMP-1 and LMP-2B but is unlikely to significantly regulate EBNA expression via Cp under normal growth conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956945      PMCID: PMC1642179          DOI: 10.1128/JVI.00897-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  87 in total

1.  Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C.

Authors:  R Touitou; M Hickabottom; G Parker; T Crook; M J Allday
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses.

Authors:  Bo Zhao; Rozenn Dalbiès-Tran; Hua Jiang; Ingrid K Ruf; Jeffery T Sample; Fred Wang; Clare E Sample
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP).

Authors:  Mark Hickabottom; Gillian A Parker; Paul Freemont; Tim Crook; Martin J Allday
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

4.  In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression.

Authors:  F Kihara-Negishi; H Yamamoto; M Suzuki; T Yamada; T Sakurai; T Tamura; T Oikawa
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

5.  Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2.

Authors:  Jeffrey Lin; Eric Johannsen; Erle Robertson; Elliott Kieff
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation.

Authors:  Chitra Subramanian; Sameez Hasan; Martin Rowe; Michael Hottiger; Rama Orre; Erle S Robertson
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth.

Authors:  Seiji Maruo; Eric Johannsen; Diego Illanes; Andrew Cooper; Elliott Kieff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity.

Authors:  Jason S Knight; Erle S Robertson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines.

Authors:  Jason S Knight; Ke Lan; Chitra Subramanian; Erle S Robertson
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

10.  EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.

Authors:  Andrew Cooper; Eric Johannsen; Seiji Maruo; Ellen Cahir-McFarland; Diego Illanes; David Davidson; Elliott Kieff
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  13 in total

1.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth.

Authors:  Seiji Maruo; Yi Wu; Taku Ito; Teru Kanda; Elliott D Kieff; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  Quantitative analysis of the bidirectional viral G-protein-coupled receptor and lytic latency-associated nuclear antigen promoter of Kaposi's sarcoma-associated herpesvirus.

Authors:  Isaac B Hilton; Dirk P Dittmer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

4.  Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines.

Authors:  Bo Zhao; Jessica C Mar; Seiji Maruo; Sungwook Lee; Benjamin E Gewurz; Eric Johannsen; Kristina Holton; Renee Rubio; Kenzo Takada; John Quackenbush; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

5.  Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.

Authors:  Horng-Shen Chen; Kayla A Martin; Fang Lu; Lena N Lupey; Joshua M Mueller; Paul M Lieberman; Italo Tempera
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

6.  Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1.

Authors:  Sungwook Lee; Shuhei Sakakibara; Seiji Maruo; Bo Zhao; Michael A Calderwood; Amy M Holthaus; Chiou-Yan Lai; Kenzo Takada; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.

Authors:  Alexander M Price; Joshua E Messinger; Micah A Luftig
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

8.  Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.

Authors:  Sizun Jiang; Bradford Willox; Hufeng Zhou; Amy M Holthaus; Anqi Wang; Tommy T Shi; Seiji Maruo; Peter V Kharchenko; Eric C Johannsen; Elliott Kieff; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

9.  Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements.

Authors:  Michael J McClellan; Sarika Khasnis; C David Wood; Richard D Palermo; Sandra N Schlick; Aditi S Kanhere; Richard G Jenner; Michelle J West
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

10.  Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes.

Authors:  Marie L Hertle; Claudia Popp; Sabine Petermann; Sabine Maier; Elisabeth Kremmer; Roland Lang; Jörg Mages; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2009-07-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.